secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-05-12T20:31:11+00:00
Accession:  0001193125-26-219610
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Inhibikase Q1 2026 net loss $16.4M; first patient enrolled in Phase 3 PAH study IMPROVE-PAH
--------------------------------------------------------------------------------

- Net loss $16.4M ($0.10 EPS) vs $13.7M ($0.15) in Q1 2025; cash & equivalents $170.4M as of Mar 31, 2026.
- First patient enrolled in registrational Phase 3 IMPROVE-PAH study for IKT-001 in PAH; EMA approved 12 EU countries, total 16 countries.
- R&D expenses $10.8M (incl. one-time non-cash $7.4M from CorHepta acquisition in prior year); SG&A $7.4M.
- Upcoming presentations at ATS May 17 and 20, 2026 on safety/tolerability/PK and preclinical efficacy of IKT-001.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/0001193125-26-219610-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526219610/d119997d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-219610

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer